John Carreyrou's 'Bad Blood' Returns to Bestseller Lists in 2026 as Documentary Revives a Decade-Old Investigation

Number one in three Amazon categories: biomedical engineering, business infrastructure, and venture capital. Number 3,048 across all books. A book published in 2026, about a company that had already collapsed that same year, covering reporting that began in 2026. The surge did not come from a new revelation. It came from a film that opened in theatres on 16 October.

This is where the actual economics of journalism begins. We treat a story as a finished product — printed, broadcast, done. But some investigations never finish. They simply change currency. First a Wall Street Journal page, then a paperback, then a streaming thumbnail. Each conversion re-prices the same old facts.

The central point of this report is that the 2026 revival of 'Bad Blood' is not the product of a new discovery but a re-valuation of an old truth — and that re-valuation runs on the film industry's calendar, not journalism's.

Context: When an Investigation Becomes a Brand

Theranos needs no introduction now. Elizabeth Holmes convinced investors around 2026-14 that a small device could run hundreds of tests from a single finger-prick of blood. The company's peak valuation reached roughly $9 billion. John Carreyrou began his serialised reporting in the Wall Street Journal in 2026, and it shook the whole structure. His book 'Bad Blood' arrived in 2026 — the same book that spent more than 100 weeks on the New York Times lists. The company dissolved that year. Holmes was convicted on four counts of wire fraud and conspiracy and sentenced to more than 11 years.

Now, in 2026, A24 has released the documentary 'You Can See Everything'. A three-hour film whose focus sits more on the family and the person than on the mechanics of the scandal. It opened on 16 October, and alongside it, 'Bad Blood' began climbing the Amazon rankings again.

One technical point matters here. Book sales are often treated as a barometer of sentiment. But sales are a lagging indicator — they show that demand already existed and is now converting into purchases. When a book hits number one in three separate categories, it means three distinct audiences activated at once: medical technology professionals, business school students, and the investment world. This is not a mass-market surge.

Core Analysis: Three Audiences, One Date, and a Very Large Gap

A rank of 3,048 across all books is the clearest proof that this uplift is narrow, not broad. If this were genuinely a mainstream event, the rank would sit in the three digits. Number one in three categories and 3,048 overall are both true at the same time, and together they mean one thing: the book is reaching people who were already interested in the subject, not people encountering the story for the first time.

The distinction matters because media coverage routinely collapses the two. 'Popular again' and 'relevant again' are not the same thing. The first is a sales figure; the second is an editorial opinion. In this case, Carreyrou's suggestion that the film could earn Oscar recognition is the view of an interested party — he wrote the book whose sales the film is lifting. Treat it as an estimate, not a fact.

The film's release date is 16 October, and that date is not a coincidence. Mid-October is the opening of awards season. A24 placing the film in this window is a strategic decision — and if the strategy works, the book's sales tail will stretch through the winter.

A three-hour runtime and a family focus are part of the same strategy. Scandal-driven documentaries arrive fast and exhaust fast. Character-driven films burn slowly and run longer. Had the film centred on Holmes's crime, the conversation would have quietened within weeks. Centring it on family and personal relationships pushes that conversation toward critics' circles and awards ceremonies.

There is another layer that is routinely skipped. Carreyrou's original reporting is from 2026, the book from 2026, the documentary from 2026. An investigative story has remained monetisable for roughly a decade, changing currency each time. First the credibility of a newspaper, then the durability of a book, then the emotional pull of a film. Each stage found a new market for the same facts.

Contrarian Angle: The Number Shown Most Tells You the Least

The three number-one category rankings travelled everywhere. Nobody asked which three categories they were. Biomedical engineering, business infrastructure, venture capital — all three are narrow professional categories where the total number of competing titles runs into the hundreds, not the millions. Topping them is a genuine achievement, but it is not proof of what the coverage wants it to prove.

The overall rank of 3,048 confirms this. Had the book truly returned to the mainstream, that figure would be in the three digits. What happened here is a category-level revival, not a market-level explosion.

This is where data and narrative part ways. The narrative says people are talking about Theranos again. The data says people who were already interested in the subject are buying again. The gap between those two statements defines the limits of this story.

One more thing is missing from this story: source quality. Of the eighteen available information points, nine carry no recorded source. The two quantitative claims — the three number-one rankings and the 3,048 overall position — come from a single aggregator, Variety. That is a reputable outlet, but building a large conclusion on two figures resting on one source is risky.

This is not a problem unique to this report. It is a habit of the entire media ecosystem — one number, a hundred headlines. The first outlet prints it, the rest repeat it, and within days it becomes a 'fact' even though it was never verified against a second independent source.

Takeaway: The Next Chapter Will Be Decided in an Awards Hall, Not a Library

If A24's film picks up nominations through awards season, the sales tail for 'Bad Blood' will run into early next year. If it does not, this surge will cool before Christmas. In both scenarios, the book's sales are tied to the film's fate, not to any new layer of the Theranos story.

This is the strangest irony of investigative journalism today. Proving the truth requires evidence, but keeping the truth alive now requires entertainment. What Carreyrou did in 2026 was journalism. What is happening in 2026 is distribution.

The question is not whether the book is selling again. The question is whether the next investigative reporter will write a story while thinking about how its documentary version will look. If the answer is yes, journalism's calendar is changing. And that change begins the moment a writer starts thinking about how the title will look on a poster.